# Ivonescimab使鱗狀非小細胞肺癌患者的死亡風險降低34%，優於標準治療。

*biotech · news · 2026-05-31 · STAT*

## Key points

- Ivonescimab使鱗狀非小細胞肺癌患者的死亡風險降低34%。
- Ivonescimab的關鍵臨床試驗由Akeso Therapeutics全程在中國進行。
- 根據試驗結果，Summit Therapeutics在中國以外地區開發Ivonescimab。
- 試驗結果於美國臨床腫瘤學會（ASCO）發表，並同步刊登於《刺胳針》期刊。

CHICAGO — Ivonescimab, a drug that combines the activity of two of the best-selling cancer medicines, reduced the risk of death in patients with squamous non-small cell lung cancer by 34% compared to a standard treatment in a clinical trial conducted entirely in China by the drug’s developer, Akeso Therapeutics, according to data presented Sunday. The result, oncologists say, exceeded their expectations, and it appears it could generate optimism for the drug, which is being developed outside China by Summit Therapeutics. But the data also are likely to fuel debate on issues like the role of China in drug development and the future of cancer treatments. The results were presented here at the annual meeting of the American Society of Clinical Oncology and are being published simultaneously in The Lancet. Robert Duggan, Summit’s co-CEO and chairman, said that the data mean the company has “a very valuable business with a very valuable product that is in its early stages.” Akeso had no comment for this story.

**Companies:** Summit Therapeutics, Akeso Therapeutics
**Countries:** China

[Read the full story on STAT](https://www.statnews.com/2026/05/31/squamous-cell-lung-cancer-akeso-summit-harmoni-asco-2026/)

---

Canonical: https://newsio.io/zh-TW/n/0611e472-6463-4797-99ba-932448fa406b/ivonescimab34summit-therapeutics
Summarized by Newsio from STAT. https://newsio.io/how-it-works